Compounds > rasagiline
Page last updated: 2024-09-03

rasagiline and Movement Disorders

rasagiline has been researched along with Movement Disorders in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barker, RA; Evans, JR1
Goetz, CG1
Konitsiotis, S1

Reviews

3 review(s) available for rasagiline and Movement Disorders

ArticleYear
Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's disease.
    Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:8

    Topics: Disease Progression; Endpoint Determination; Humans; Indans; Movement Disorders; Neuroprotective Agents; Parkinson Disease; Posture; Reflex, Abnormal; Research Design; Treatment Outcome

2011
Movement disorders: understanding clinical trials.
    The Lancet. Neurology, 2005, Volume: 4, Issue:1

    Topics: Antiparkinson Agents; Clinical Trials as Topic; Humans; Indans; Movement Disorders; Neuroprotective Agents; Parkinson Disease; Randomized Controlled Trials as Topic; Research Design; Tomography, Emission-Computed, Single-Photon

2005
Novel pharmacological strategies for motor complications in Parkinson's disease.
    Expert opinion on investigational drugs, 2005, Volume: 14, Issue:4

    Topics: Administration, Cutaneous; Animals; Antiparkinson Agents; Brain; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Clinical Trials as Topic; Dopamine Agonists; Drug Delivery Systems; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Indans; Levodopa; Liposomes; Monoamine Oxidase Inhibitors; Motor Neurons; Movement Disorders; Nitriles; Parkinson Disease; Receptors, Glutamate; Signal Transduction

2005